An Update & Analysis of the Macular Degeneration Complement Landscape

Time: 2:30 pm
day: Track B - Day 1 PM


  • Assessing the current status of complement therapeutics in clinical development
  • What are the implications of month 24 Phase 3 data from APELLIS and Month 12 Phase 3 data from IVERIC for geographic atrophy treatment ( intravitreal C3 and C5 therapy)?
  • What is the potential of gene therapy and systemic approaches in clinical development vs intravitreal therapies for macular degeneration?